Related Experiment Video

Updated: Nov 5, 2025

White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice
06:16

White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice

Published on: September 9, 2025

217

Perirenal and subcutaneous fat differently affect outcomes in newly diagnosed classical Hodgkin lymphoma patients

Marko Lucijanic1,2, Renata Huzjan Korunic2,3, Marija Ivic1

  • 1Hematology Department, University Hospital Dubrava, Zagreb, Croatia.

Hematological Oncology
|May 15, 2021
PubMed
Abstract

No abstract available in PubMed .

Keywords:
body mass indexcachexiacancerobesityvisceral fat

More Related Videos

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

765
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.9K

Related Experiment Videos

Last Updated: Nov 5, 2025

White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice
06:16

White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice

Published on: September 9, 2025

217
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

765
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.9K

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

63
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
63
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

43
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
43

Articles linked to this work by shared authors, journal, and citation graph.

Late-Onset Neutropenia and Hypogammaglobulinemia After Dose-Adjusted R-EPOCH in Unfavorable Diffuse Large B-Cell Lymphoma.

Life (Basel, Switzerland)·2026

Longitudinal changes in left atrial function during chronic ibrutinib therapy: a prospective observational study.

Frontiers in cardiovascular medicine·2026

Hepatotoxicity Profile of Bortezomib-Containing Regimens for First-Line Multiple Myeloma Treatment.

Pharmaceuticals (Basel, Switzerland)·2026

Chronotherapy in Hematological Malignancies: Evaluating the Rationale and Evidence.

Pharmacology research & perspectives·2026

Hemoglobin Trajectories on SGLT2 Inhibitor Therapy in Heart Failure: Anemia Marks Adverse Prognosis While Erythrocytosis Is Transient and Not Associated with Adverse Outcomes.

Journal of clinical medicine·2026

Symptomatic Osteoarthritis May Be Associated with Higher Symptom Burden and Thrombotic Risk in Patients with Myeloproliferative Neoplasms: A Prospective Two-Centre Study.

Journal of clinical medicine·2026

NUDT21 Promotes Myelodysplastic Syndrome Progression by Regulating SRSF2 Expression via Alternative Polyadenylation.

Hematological oncology·2026

Clinical Impact of CTLA4 and LAG3 Single-Nucleotide Polymorphisms in Multiple Myeloma Patients Treated With BCMA CAR T-Cell Therapy.

Hematological oncology·2026

Clinicopathologic Features and Survival Determinants of Hepatosplenic T-Cell Lymphoma: A Pooled Patient-Level Dataset Analysis.

Hematological oncology·2026

Host Fitness: A Missing Dimension of Precision Medicine in Older Acute Myeloid Leukemia.

Hematological oncology·2026

Venetoclax-Based Regimens in Newly Diagnosed FLT3-Mutated Older or Unfit Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Comparative and Single-Arm Outcomes.

Hematological oncology·2026

Impact of Residual Disease Localization Before Allogeneic Hematopoietic Stem Cell Transplantation on Outcomes in Adult T-Cell Leukemia-Lymphoma.

Hematological oncology·2026

MAGEA6 Promoted Gastric Cancer Progression by Activating Mitophagy.

Molecular carcinogenesis·2026

NET-Associated Inflammatory Markers in Head and Neck Squamous Cell Carcinoma: Bioinformatic Prioritization and Exploratory Serum Assessment in Patients Undergoing Radiotherapy.

Molecular carcinogenesis·2026

Impact of PD-1 and PD-L1 inhibitors on patient-reported outcomes in esophageal squamous cell carcinoma: a systematic review of clinical trials.

Current medical research and opinion·2026

Perfusion beyond Margin in Hepatocellular Carcinoma: A Contrast-enhanced US Feature Related to Tumor Invasiveness and Prognosis.

Radiology·2026

Prognostic Value of Primary Tumor and Immune Organ Metabolic Parameters Derived from Pretreatment 18F-FDG PET/CT in Gastric Adenocarcinoma: A Retrospective Survival Analysis.

Molecular imaging and radionuclide therapy·2026

Cell-based polygenic risk scores predict clinical progression and prioritize network-based therapeutic targets in Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us